BioWorld - Friday, January 30, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

3D illustration of headache
Neurology/psychiatric

Bright Minds’ BMB-201 shows promise in vascular headache model

Sep. 5, 2025
No Comments
Bright Minds Biosciences Inc. has released preclinical results for BMB‑201, a selective 5-HT2A/2C receptor agonist, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 is designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A activation.
Read More
Neurology/psychiatric

Humanwell discovers new Nav1.8 blockers

Sep. 4, 2025
Humanwell Pharmaceutical US Inc. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.
Read More
Neurology/psychiatric

Aglaeapharma discovers new α2-adrenoceptor agonists

Sep. 3, 2025
Aglaeapharma Inc. has described compounds acting as α2-adrenoceptor agonists reported to be useful for the treatment of rhinitis, pain, insomnia, inflammatory disorders, glaucoma, cancer, anesthesia and acute kidney injury, among others.
Read More
Neurology/psychiatric

Aconcagua Bio divulges new calcitonin receptor and amylin receptor agonists

Sep. 3, 2025
Aconcagua Bio Inc. has synthesized calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone disease, periodontal disease, metabolic dysfunction-associated steatotic liver disease MASLD), osteogenesis imperfecta and cardiovascular disorders, among others.
Read More
Neurology/psychiatric

Shanghai Shenshi Wise Technology patents new Kv1.3 blockers

Sep. 3, 2025
Shanghai Shenshi Wise Technology Co. Ltd. has disclosed potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers reported to be useful for the treatment of Alzheimer’s disease, obesity, kidney fibrosis, type 2 diabetes and more.
Read More
Female scientist looking through microscope
Neurology/psychiatric

PARP7 inhibition relieves EAE by modulating type I interferon signaling

Sep. 3, 2025
No Comments

The regulation of type I interferon (IFN-1) signaling is crucial for fine-tuning the innate immune response to combat pathogens, fight cancer and prevent autoimmune diseases. Disrupted IFN-1 signaling plays a key role in autoimmune and inflammatory diseases. Therefore, understanding how IFN-1 production and signaling are regulated could reveal new approaches for treating conditions driven by this pathway.


Read More
Demyelination of a neuron
Neurology/psychiatric

Grant supports evaluation of Neucore’s exosome platform for CMT1A

Sep. 3, 2025
No Comments
Neucore Bio Inc. has received a $350,000 STTR phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the company’s targeted exosome platform to deliver an RNA-based therapy to treat Charcot-Marie-Tooth disease type 1a (CMT1A).
Read More
Illustration of muscle tissue anatomy
Musculoskeletal

miR-33a/b are potential targets in muscular dystrophies: study

Sep. 3, 2025
No Comments
Researchers have identified a potential therapeutic target for muscular dystrophies, a group of genetic disorders characterized by progressive muscle weakness and degeneration. The study reveals that inhibiting the microRNA (miRNA) known as miRNA-33 can significantly improve muscle regeneration and ameliorate the dystrophic phenotype in animal models.
Read More